SecBot SecBot
SECBOTREPLAY Home › Report › EW

EW · Edwards Lifesciences Corp (EW) filed a DEFA14A proxy statement for its…

Edwards Lifesciences Corp · DEFA14A filed Mar 26, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Mar 26, 2026 at 16:07 ET

Edwards Lifesciences Corp (EW) filed a DEFA14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing is a routine, management-sponsored solicitation requesting shareholder approval for the election of nine director nominees, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan. The document includes a stockholder presentation highlighting the company's innovation strategy and board composition.

  • The filing is a Definitive Additional Materials (DEFA14A) for the 2026 Annual Meeting.
  • The Board is requesting shareholder approval for four proposals: election of nine directors, advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan.
  • The document includes a Spring 2026 Stockholder Presentation with forward-looking statements about the company's strategy and innovation.
  • The board composition includes nine nominees with extensive experience in the medical technology industry.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access